Tirzepatide (20mg)
Tirzepatide is a 39-amino acid dual GLP-1/GIP agonist, approved (Mounjaro®/Zepbound™) for T2D and obesity. 20 mg vial for intermediate cycles.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
Research monograph
See the full Tirzepatide encyclopedia page with mechanism, evidence tier, related variants and research context.
How It Works
Tirzepatide activates both GLP-1 and GIP receptors, enhancing glucose-dependent insulin secretion, inhibiting glucagon, slowing gastric emptying, and reducing appetite through central mechanisms.
Quick Start
- Reconstitution: Add 2.0 mL of bacteriostatic water → 10.0 mg/mL concentration.
- Weekly range: 2.5–15 mg once weekly.
- Storage: Lyophilized: 2–8 °C; reconstituted: 2–8 °C.
Gradual Titration (2 mL = 10.0 mg/mL)
Route: Subcutaneously | Frequency: Once weekly
| Week | Dose | Units (per injection) |
|---|---|---|
| Weeks 1–4 | 2.5 mg | 25 Units (0.25 mL) |
| Weeks 5–8 | 5.0 mg | 50 Units (0.50 mL) |
| Weeks 9–12 | 7.5 mg | 75 Units (0.75 mL) |
| Weeks 13–16 | 10.0 mg | 100 Units (1.00 mL) |
| Weeks 17+ | 12.5–15 mg | 125–150 Units (1.25–1.50 mL) |
Studies report administration once weekly on the same day. Increase dose gradually every 4 weeks.
Related compounds
Reconstitution Steps
- Withdraw 2.0 mL of bacteriostatic water.
- Inject slowly down the side wall.
- Swirl gently.
- Refrigerate at 2–8 °C.
Protocol Overview
- Goal: Weight management or glycemic control.
- Schedule: 1× weekly, gradual titration.
Dosing Protocol
- Starting dose: 2.5 mg/wk for 4 weeks.
- Titration: +2.5 mg every 4 weeks.
- Max dose: 15 mg/wk.
- Half-life: ~5 days.
- Break between cycles: Gradual dose reduction before discontinuation to avoid rebound effects.
Washout & Cycle Restart
When can I restart?
Gradual dose reduction before discontinuation to avoid rebound effects.
Minimum wait period: 4 weeks
Storage Instructions
- Lyophilized: 2–8 °C (or −20 °C for long-term).
- Reconstituted: 2–8 °C, use within 28 days.
Important Notes
- FDA-approved (Mounjaro® / Zepbound™).
- Gradual titration reduces GI side effects.
- Check for thyroid history (MTC/MEN2).
- Monitor glycemia if taking other anti-diabetic medications.
Potential Benefits & Side Effects
Potential Benefits:
- Clinically proven weight loss (>20% in SURMOUNT studies).
- Improved glycemic control.
- Reduction in cardiovascular risk factors.
- Weekly administration.
Potential Side Effects:
- Nausea, diarrhea, constipation (common, reduced with titration).
- Decreased appetite.
- Injection site reactions.
- Rare: pancreatitis, cholelithiasis.
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Thyroid C-cell tumors (medullary thyroid carcinoma)
Same warning as GLP-1 RAs. C-cell tumors in rodents. Contraindicated in MTC/MEN 2.
📄 FDA Boxed Warning — Mounjaro® LabelAcute pancreatitis
Risk of acute pancreatitis. Reported in post-marketing surveillance.
📄 FDA Label — Mounjaro®References
- NEJM — SURMOUNT-1 — Tirzepatide for obesity (2022)
View Source - NEJM — SURPASS-1 — Tirzepatide vs placebo in T2D
View Source - SURPASS-2: Tirzepatide vs Semaglutide — The Lancet (2021) — SURPASS-2: Tirzepatide vs Semaglutide
View Source
Recommended Supplements
Vitamin B12 (Methylcobalamin)
Vitamin D3 + K2
Omega-3 Fish Oil (EPA/DHA)
Protein / Collagen
Fiber Supplement (Psyllium)
External Sources & Regulatory Status
Regulatory Approvals
Mounjaro® / Zepbound® · Type 2 diabetes / Obesity (2022)
Mounjaro® · Type 2 diabetes (2022)
Mounjaro® · Type 2 diabetes (2023)
Mounjaro® · Type 2 diabetes (2024)
Mounjaro® · Type 2 diabetes / Obesity (2023)
Mounjaro® · Type 2 diabetes (2023)
Approved worldwide (6+ countries)
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →